Table 1 Baseline characteristics according to consolidation compliance

Age (years)

Mean (SD)

Mean (SD)

Mean (SD)

56.00 (7.21)

57.08 (6.48)

55.57 (7.44)

0.07

Median (IQR)

Median (IQR)

Median (IQR)

57.47 (51.57–61.74)

58.23 (52.40–62.28)

56.76 (51.08–61.49)

Sex

Male

236 (57.00 %)

62 (52.54 %)

174 (58.78 %)

0.25

Female

178 (43.00 %)

56 (47.46 %)

122 (41.22 %)

Haemoglobin (g/dL)

>10.5 normal

251 (60.63 %)

67 (56.78 %)

184 (62.16 %)

0.31

≤10.5 abnormal

163 (39.37 %)

51 (43.22 %)

112 (37.84 %)

Platelets (×10⁹ per L)

>150 normal

369 (89.13 %)

107 (90.68 %)

262 (88.51 %)

0.52

≤150 abnormal

45 (10.87 %)

11 (9.32 %)

34 (11.49 %)

Creatinine (μmol/dL)

≤1.2 normal

326 (78.74 %)

94 (79.66 %)

232 (78.38 %)

0.77

>1.2 abnormal

88 (21.26 %)

24 (20.34 %)

64 (21.62 %)

LDH (U/L)

≤190 normal

59 (14.25 %)

24 (20.34 %)

35 (11.82 %)

0.03

>190 abnormal

355 (85.75 %)

94 (79.66 %)

261 (88.18 %)

ISS stage

1

180 (43.48 %)

44 (37.29 %)

136 (45.95 %)

0.26

2

162 (39.13 %)

50 (42.37 %)

112 (37.84 %)

3

72 (17.39 %)

24 (20.34 %)

48 (16.22 %)

IgA isotype

IgA

81 (19.57 %)

25 (21.19 %)

56 (18.92 %)

0.60

Not IgA

333 (80.43 %)

93 (78.81 %)

240 (81.08 %)

Del(13q)

absent

214 (51.69 %)

61 (51.69 %)

153 (51.69 %)

0.99

present

200 (48.31 %)

57 (48.31 %)

143 (48.31 %)

Del(17p)

absent

385 (93.00 %)

110 (93.22 %)

275 (92.91 %)

0.91

present

29 (7.00 %)

8 (6.78 %)

21 (7.09 %)

T(4;14)

absent

331 (79.95 %)

98 (83.05 %)

233 (78.72 %)

0.32

present

83 (20.05 %)

20 (16.95 %)

63 (21.28 %)

Treatment arm

A experimental

200 (48.31 %)

53 (44.92 %)

147 (49.66 %)

0.38

B control

214 (51.69 %)

65 (55.08 %)

149 (50.34 %)